Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis - Effect of different treatments

Journal of Rheumatology

Volumn 41, Issue 4, 2014, Pages 714-722

  Di Minno, Matteo Nicola Dario ^a   Iervolino, Salvatore ^b   Peluso, Rosario ^a   Di Minno, Alessandro ^a   Ambrosino, Pasquale ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

Author keywords

Fibrinolysis; Hemostasis; Minimal disease activity; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; BLOOD CLOTTING FACTOR 8; D DIMER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VON WILLEBRAND FACTOR; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; RISK FACTOR; THROMBOSIS; TRADITIONAL MEDICINE; TREATMENT DURATION; AGE; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 84897417669     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130850     Document Type: Article

References (38)

1. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: The link between inflammation and atherothrombosis. Semin Thromb Hemost 2012;38:497-505.
2. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009;22:61-73.
3. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30:1014-26.
4. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216:152-5.
5. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
6. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47.
7. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002;90: 19G-26G.
8. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:2580-6.
9. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 2002;46:2268-79.
10. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 2012;7 Suppl 2:S97-8.
11. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012;39:334-6.
12. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008;31:175-9.
13. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
14. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
15. Di Minno MN, Tufano A, Guida A, Di Capua M, De Gregorio AM, Cerbone AM, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res 2011;127:193-7.
16. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
17. Di Minno MN, Palmieri V, Lombardi G, Pezzullo S, Cirillo F, Di Somma C, et al. Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. Thromb Res 2009;124:711-3.
18. Di Minno MN, Pezzullo S, Palmieri V, Di Somma C, Lupoli R, Valle D, et al. Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. Thromb Res 2010;126:e434-8.
19. Di Minno MN, Dentali F, Veglia F, Russolillo A, Tremoli E, Ageno W. Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study. Thromb Haemost 2013;109:167-9.
20. Di Gioia L, Zincarelli C, Di Minno MN, Rengo G, Peluso R, Spanò A, et al. Effectiveness of a rehabilitative programme in improving fatigue and function in rheumatoid arthritis patients treated with biologics: a pilot study. Clin Exp Rheumatol 2013;31:285-8.
21. Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, et al; CaRRDS study group. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol 2012;39:1042-6.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
23. Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 2006;24:580-3.
24. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 2004;279:18127-36.
25. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001;40:640-4.
26. Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 2010;8:285-92.
27. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007;5 Suppl 1:132-42.
28. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-828.
29. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009;113:5049-57.
30. Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 1997;16:254-60.
31. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010;28:254-7.
32. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705-12.
33. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-64.
34. Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology 2013;52:62-7.
35. Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 2013;65:141-7.
36. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R; on behalf of the CaRRDs study group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumor necrosis factor α blockers. Ann Rheum Dis 2013 Jun 14 (E-pub ahead of print).
37. Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Tarantino G, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther 2012;14:R211.
38. Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G, et al. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol 2013;32:743-53.